The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Net Margin % or its related term are showing as below:
XMAD:ROVI'
s Net Margin % Range Over the Past 10 Years
Min: 5.9 Med: 16.23 Max: 24.42
Current: 17.79
XMAD:ROVI's Net Margin % is ranked better than 84.31% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XMAD:ROVI: 17.79
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Laboratorios Farmaceuticos Rovi Net Margin % Related Terms
Laboratorios Farmaceuticos Rovi Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Net Margin % Chart
XMAD:ROVI vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Net Margin % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Net Margin % of 6.22% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 62% below median its historical median of 16.23. Over the past decade, Laboratorios Farmaceuticos Rovi's Net Margin % has ranged from 5.90 to 24.42. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #150 out of 956 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Laboratorios Farmaceuticos Rovi's Net Margin % too high?
Laboratorios Farmaceuticos Rovi's current Net Margin % of 6.22% is 62% below median its 10-year median of 16.23. Over the past 10 years, this metric has ranged from a low of 5.90 to a high of 24.42. The Drug Manufacturers industry median Net Margin % is 5.56. Laboratorios Farmaceuticos Rovi's value of 6.22% is 11.9% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #150 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #150 out of 956 companies for Net Margin %. This places Laboratorios Farmaceuticos Rovi in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Laboratorios Farmaceuticos Rovi's value of 6.22% is 11.9% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Net Margin % has ranged from 5.90 to 24.42 over the past decade. While the company's 10-year median is 16.23 vs. the industry median of 5.56, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Net Margin % of 6.22% is 11.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Net Margin % is 6.22%, which is 62% below median its own 10-year median of 16.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €59.25 — trading 16.3% above its estimated fair value. The current Net Margin % is 6.22%, which is 62% below median its 10-year median of 16.23 and 11.9% above the Drug Manufacturers industry median of 5.56. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Net Margin % is 6.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €59.25 is trading 16.3% above its estimated GF Value™ of €50.93.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Net Margin %: 6.22% (62% below median its 10-year median of 16.23)
GF Value™: €50.93 vs. price of €59.25 (16.3% above fair value)
Industry Position: 11.9% above the Drug Manufacturers median (#150 of 956)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score
Get the complete analysis for XMAD:ROVI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
